DOCS.L

Dr. Martens plc
Dr. Martens PLC - Annual Financial Report
17th June 2025, 08:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0657N
Dr. Martens PLC
17 June 2025
 

Dr. Martens plc (the "Company")

2025 Annual Report and Notice of Annual General Meeting

Further to the announcement of its preliminary results for the financial period ended 30 March 2025 and in accordance with UK Listing Rules 6.4.1R, 6.4.3R and 10.6.13R, the Company announces that the following documents have been submitted in unedited full text to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism:

·      Annual Report and Accounts for the financial period ended 30 March 2025 (the "2025 Annual Report")

·      Notice of the 2025 Annual General Meeting (the "2025 Notice of Meeting"), which will take place at 9.30am on Thursday 10 July 2025 at 1-11 Hawley Crescent, Camden, London, NW1 8NP

·      Proxy form for the 2025 Annual General Meeting

·      Rules of the Dr. Martens Long Term Incentive Plan

In compliance with rule 6.3.5R of the Disclosure Guidance and Transparency Rules, the 2025 Annual Report and 2025 Notice of Meeting are also available in unedited full text on the Company's website, www.drmartensplc.com.


For further information, please contact:
Paul Rolling, Head of Secretariat
+447584243562

Bethany Barnes, Director of Investor Relations
+447825187465


ENDS


About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. "Docs" or "DMs" were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned "1460" boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. Further information can be found at https://www.drmartensplc.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSGPUGWQUPAGQQ]]>
TwitterFacebookLinkedIn